|
Wednesday, July 7, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)
A Conversation with the Investigators: Ovarian CancerA Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual MeetingJoin us on Wednesday, July 7th for this CME/MOC-accredited webinar Faculty
Michael J Birrer, MD, PhD
Vice Chancellor, UAMS Director, Winthrop P Rockefeller Cancer Institute Director, Cancer Service Line University of Arkansas for Medical Sciences Little Rock, Arkansas Kathleen Moore, MD The Virginia Kerley Cade Endowed Chair in Cancer Development Associate Director, Clinical Research Director, Oklahoma TSET Phase I Program Stephenson Cancer Center Associate Professor, Section of Gynecologic Oncology Director, Gynecologic Oncology Fellowship Department of Obstetrics and Gynecology University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma
Richard T Penson, MD, MRCP
Associate Professor of Medicine Harvard Medical School Clinical Director, Medical Gynecologic Oncology Massachusetts General Hospital Boston, Massachusetts Moderator Neil Love, MD Research To Practice Miami, Florida Ovarian Cancer (OC)
Target Audience Learning Objectives
CME Credit Form Accreditation Statement Credit Designation Statement American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Disclosure Policy FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process: Dr Birrer — Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: VBL Therapeutics. Dr Moore — Consulting Agreements: Aravive Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, ImmunoGen Inc, Merck, Mersana Therapeutics, Myriad Genetic Laboratories Inc, Sorrento Therapeutics, Tarveda Therapeutics, Tesaro, A GSK Company, VBL Therapeutics; Contracted Research: PTC Therapeutics, US Department of Defense. Dr Penson — Research Funding: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, VBL Therapeutics; Royalties: BMJ Publishing Group Ltd, Elsevier, Wolters Kluwer; Scientific Advisory Board: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Care4ward (Unpaid), Clovis Oncology, Curio Science (Vaniam Group), Eisai Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Mersana Therapeutics, Nexus Group Global, Pieris Pharmaceuticals Inc, Roche Laboratories Inc, Sutro Biopharma, Syndax Pharmaceuticals Inc, Tesaro, A GSK Company, VBL Therapeutics.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters |